Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007

BACKGROUND: Due to its high and consistent expression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) represents an ideal target for molecular imaging and targeted therapy using highly specific radiolabeled PSMA ligands. To address the continuously growing clinical demand for...

Descripción completa

Detalles Bibliográficos
Autores principales: Robu, Stephanie, Schmidt, Alexander, Eiber, Matthias, Schottelius, Margret, Günther, Thomas, Hooshyar Yousefi, Behrooz, Schwaiger, Markus, Wester, Hans-Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897267/
https://www.ncbi.nlm.nih.gov/pubmed/29651565
http://dx.doi.org/10.1186/s13550-018-0382-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897267/
https://www.ncbi.nlm.nih.gov/pubmed/29651565
http://dx.doi.org/10.1186/s13550-018-0382-8

Ejemplares similares